Skip to content

US · VCYT · MEDICAL - DIAGNOSTICS & RESEARCH

Veracyte, Inc. (VCYT) intrinsic value and stock valuation

$25.13as of 2026-11-21 · Mkt cap 3.68B

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Veracyte, Inc. DCF and intrinsic value

InvestorsCraft values VCYT with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from VCYT’s statements →

Veracyte, Inc. Graham Number

Graham Number: $17.79d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →

Healthcare · Medical - Diagnostics & Research South San Francisco, CA 94080 veracyte.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$517.1M+34.5% 5y CAGRd
20112025
Net income
$66.4M
20112025
Free cash flow
$126.6M
20112025
Total equity
$1.31B+25.5% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$517.1M$445.8M$361.1M$296.5M$219.5M
Operating income$74.2M$16.1M-$-85.8M-$-41.08M-$-81.9M
Net income$66.4M$24.1M-$-74.4M-$-36.56M-$-75.56M
EPSd$823.5K$308.9K-$-1.02M-$-510.97K-$-1.11M
Operating cash flow$136.3M$75.1M$44.2M$7.54M-$-31.62M
Capital expenditure-$-9.68M-$-11.29M-$-9.96M-$-8.55M-$-5.38M
Free cash flow$126.6M$63.8M$34.3M-$-1.01M-$-37M
Total assets$1.41B$1.3B$1.11B$1.16B$1.19B
Total debt$39.7M$50.7M$12.6M$14.7M$18.9M
Net debt-$-322.92M-$-188.35M-$-203.82M-$-139.53M-$-154.34M
Total equity$1.31B$1.18B$1.04B$1.08B$1.1B
Cash and short-term investments$412.9M$289.4M$216.5M$178.9M$177.2M
Income statement
20252024202320222021
Revenue$517.1M$445.8M$361.1M$296.5M$219.5M
Cost of revenue$157.1M$147.6M$112.9M$101.6M$74.4M
Gross profit$360.1M$298.1M$248.2M$195M$145.1M
Research and development expenses$70.8M$69.3M$57.3M$40.6M$29.8M
Selling, general and administrative expenses$211M$206M$184.2M$174.1M$181.2M
Other expenses$4.13M$6.67M$92.4M$21.4M$16M
Operating expenses$285.9M$282M$333.9M$236M$227M
Cost and expenses$443M$429.6M$446.9M$337.6M$301.4M
Interest income$0.00$11.2M$7.34M$1.97M$140K
Interest expense$0.00$0.00$10K$200K$240K
Depreciation and amortization$21.4M$23.5M$27.2M$29.3M$21.2M
Ebitda$89.6M$49.2M-$-49.41M-$-6.98M-$-60.18M
Operating income$74.2M$16.1M-$-85.8M-$-41.08M-$-81.9M
Total other income/expenses, net-$-5.95M$9.6M$9.18M$4.65M$250K
Income before tax$68.2M$25.7M-$-76.61M-$-36.43M-$-81.65M
Income tax expense$1.85M$1.61M-$-2.21M$130K-$-6.09M
Net income$66.4M$24.1M-$-74.4M-$-36.56M-$-75.56M
Weighted average shares outstanding$78.6M$76.5M$72.6M$71.6M$67.9M
Weighted average diluted shares outstanding$80.6M$78.2M$72.6M$71.6M$67.9M
Balance sheet
20252024202320222021
Cash and short-term investments$412.9M$289.4M$216.5M$178.9M$177.2M
Net receivables$44.7M$46.5M$40.4M$44M$41.5M
Inventory$20.6M$21.8M$16.1M$14.3M$11.2M
Total current assets$488.4M$372.3M$285.6M$248.6M$243.1M
Property, plant and equipment, net$58.8M$71.1M$30.9M$30.9M$31.1M
Goodwill and intangible assets$856.3M$848.1M$791.6M$870.8M$910.6M
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$917.6M$927.8M$829.3M$907.8M$944.7M
Total assets$1.41B$1.3B$1.11B$1.16B$1.19B
Accounts payable$4.59M$8.63M$12.9M$11.9M$12.4M
Short-term debt$4.05M$7.5M$5.11M$4.07M$4.76M
Deferred revenue$1.16M$1.67M$2.01M$2.61M$4.65M
Total current liabilities$59.9M$78.6M$61.2M$62.6M$64.2M
Long-term debt$35.6M$43.2M$7.53M$10.7M$14.1M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$340K
Total non-current liabilities$36.5M$45.4M$9.56M$18.6M$27.2M
Capital lease obligations$39.7M$50.7M$12.6M$14.7M$17.7M
Total liabilities$96.4M$124.1M$70.8M$81.2M$91.3M
Common stock$80K$80K$70K$70K$70K
Retained earnings-$-377.63M-$-443.98M-$-468.12M-$-393.72M-$-357.16M
Accumulated other comprehensive income (loss)-$-8.21M-$-36.09M-$-24.02M-$-31.35M-$-15.08M
Total equity$1.31B$1.18B$1.04B$1.08B$1.1B
Total investments$50.3M$50.4M$0.00$24.6M$3.96M
Total debt$39.7M$50.7M$12.6M$14.7M$18.9M
Net debt-$-322.92M-$-188.35M-$-203.82M-$-139.53M-$-154.34M
Cash flow statement
20252024202320222021
Net income$66.4M$24.1M-$-74.4M-$-36.56M-$-75.56M
Depreciation and amortization$21.4M$23.5M$27.2M$25.9M$19.6M
Stock-based compensation$43.6M$36.3M$33.1M$26.7M$22.5M
Change in working capital-$-2.3M-$-20.96M-$-3.69M-$-16.38M$4.22M
Accounts receivable-$-710K-$-6.41M$3.89M-$-4.5M-$-8.57M
Inventory-$-2.86M-$-5.87M-$-1.69M-$-3.01M-$-1.46M
Accounts payable-$-1.04M-$-4.3M-$-130K$150K$5.16M
Net cash provided by operating activities$136.3M$75.1M$44.2M$7.54M-$-31.62M
Investments in property, plant and equipment-$-9.68M-$-11.29M-$-9.96M-$-8.55M-$-5.38M
Acquisitions, net-$-2.85M$5.01M$0.00$0.00-$-736.83M
Net cash used for investing activities-$-9.21M-$-56.27M$15.1M-$-29.39M-$-739.21M
Common stock issued$14.1M$20M$0.00$0.00$593.8M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities-$-4.22M$4.9M$2.84M$3.49M$596.3M
Net change in cash$123.6M$23.3M$62.3M-$-18.95M-$-176.02M
Cash at end of period$364.2M$240.6M$217.3M$155M$174M
Operating cash flow$136.3M$75.1M$44.2M$7.54M-$-31.62M
Capital expenditure-$-9.68M-$-11.29M-$-9.96M-$-8.55M-$-5.38M
Free cash flow$126.6M$63.8M$34.3M-$-1.01M-$-37M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Veracyte, Inc.

        Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.

        CEO
        Marc Stapley
        Employees
        755
        Beta
        1.93

        Explore

        Frequently asked questions

        What is the intrinsic value of Veracyte, Inc. (VCYT)?

        Veracyte, Inc. (VCYT) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is VCYT undervalued?

        VCYT trades at a price of $25.13 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.